China Nuokang Bio-Pharma Falls on NY Debut
By wchung | 28 Mar, 2026
Shares of China Nuokang Bio-Pharmaceutical Inc. fell nearly 4 percent in their trading debut Thursday after pricing at $9 per American depositary share, below their expected range.
The China-based biopharmaceutical company, which specializes in blood and cardiovascular treatments, had expected the initial public offering of 5 million ADSs to price between $10 and $12.
The company said net proceeds from the offering totaled about $32.9 million. The company plans to use the funds to grow its sales and marketing platform, for new acquisitions, for research and to expand manufacturing facilities.
Shares, which trade under the symbol “NKBP” on the Nasdaq, fell 33 cents, or 3.7 percent, to close at $8.67 with about 2.3 million shares changing hands during the session.
12/10/2009 4:53 PM NEW YORK (AP)
Articles
- Manila-Beijing Talks Resume on South China Sea, Energy Security
- India Signals Acceptance of E-commerce Tariff Moratorium but Balks at US Push for Permanent Extension
- AI Deepfakes Rampant in 2026 US Midterm Campaigns
- No Kings Rallies Against Trump Planned in Thousands of US Cities
- Indonesia's Social Media Curbs for Under-16s Create Confusion
- Tiger Woods Arrested for DUI After Florida Rollover
- BTS Tops UK Charts with Comeback Album
- Let's Be Good Again So We Can Be Great Again
- Iran-Linked Hackers Access FBI Director's Personal Email, Publish Online
- US Can Confirm Only a Third of Iran's Missile Arsenal Destroyed,